OTCMKTS:BIOVF Q3 EPS Forecast Decreased by HC Wainwright

Swedish Orphan Biovitrum (OTCMKTS:BIOVF) – Equities research analysts at HC Wainwright decreased their Q3 2026 EPS estimates for Swedish Orphan Biovitrum in a research note issued on Friday, September 11th. HC Wainwright analyst M. Kapoor now anticipates that the company will earn $0.62 per share for the quarter, down from their prior forecast of $0.63. The consensus estimate for Swedish Orphan Biovitrum’s current full-year earnings is $1.94 per share. HC Wainwright also issued estimates for Swedish Orphan Biovitrum’s Q4 2026 earnings at $0.59 EPS, FY2026 earnings at $1.91 EPS, Q1 2027 earnings at $0.61 EPS, Q3 2027 earnings at $1.04 EPS, Q4 2027 earnings at $1.01 EPS and FY2027 earnings at $3.31 EPS.

Other analysts also recently issued reports about the company. Pareto Securities downgraded Swedish Orphan Biovitrum to a “hold” rating in a report on Monday, June 29th. Barclays reissued an “overweight” rating on shares of Swedish Orphan Biovitrum in a research note on Friday, July 3rd. Finally, Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of Swedish Orphan Biovitrum in a report on Tuesday, July 21st. Four analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy”.

Swedish Orphan Biovitrum Stock Performance

Shares of Swedish Orphan Biovitrum stock opened at $48.13 on Wednesday. The business has a 50-day moving average of $48.39 and a 200 day moving average of $45.63. The stock has a market capitalization of $17.13 billion, a price-to-earnings ratio of 106.95 and a beta of 0.33. The company has a debt-to-equity ratio of 0.20, a current ratio of 0.88 and a quick ratio of 0.55. Swedish Orphan Biovitrum has a 12 month low of $29.18 and a 12 month high of $49.03.

Swedish Orphan Biovitrum Company Profile

Swedish Orphan Biovitrum AB, commonly known as Sobi, is a Swedish biopharmaceutical company focused on developing, manufacturing and commercializing therapies for rare diseases. Its principal areas of activity include hematology, immunology and specialty care, with an emphasis on conditions that have limited treatment options and relatively small patient populations.

Sobi’s portfolio includes treatments for hemophilia and other bleeding disorders, such as Elocta, Alprolix and Vonvendi, as well as medicines for immune-mediated and hematologic conditions.